Drugs / 18F-AlF-FAPi-04
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06126705 | Jul 2023 → May 2024 | — | Affiliated Hospital of North Sichuan Medical College | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-AlF-FAPi-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126705 ↗ |
| Modality | Diagnostic / imaging agent | “To evaluate the potential usefulness of 18F-AlF-FAPi-04 PET/CT for the diagnosis of primary and metastatic lesions in solid cancer.” NCT06126705 ↗ |
| Route | Intravenous | “receive intravenous administration of 18F-AlF-FAPi-04” NCT06126705 ↗ |